Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin

NCT06490198 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma
Chemotherapy Effect
Immunotherapy

Interventions

DRUG: OBI-833/OBI-821

Sponsor

Chang Gung Memorial Hospital